Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925351 · ClinicalTrials.gov registry record · Early Phase 1
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
A Early Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02925351 is a Early Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT02925351, a Early Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- RADIATION Fluorine F 18 Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-01-25 |
| Est. Completion | 2018-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02925351
The ClinicalTrials.gov registry entry for NCT02925351 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Computed Tomography is the first listed.
NCT02925351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02925351 about?
NCT02925351 is a clinical study titled "Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases". This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body...
What is the current status of trial NCT02925351?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2016-01-25. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT02925351?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fluorine F 18 Clofarabine (RADIATION).
Who is sponsoring clinical trial NCT02925351?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.